drugset
drugset / Trial / NCT00195455

Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.

NCT00195455 ↗

Phase 4 Completed 133 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.

Timeline

Start
2005-02
Primary completion
—
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject 17B-estradiol Unknown 1 mg —
Subject Trimegestone Small molecule 0.125 mg —

Indications

No indication recorded.